+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome



Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome



Archives of Ophthalmology 111(10): 1359-1366



Objective: To assess the clinical response and patient tolerance to daily infusions of both ganciclovir sodium and foscarnet sodium for the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Design and patients: Nine patients with clinically resistant cytomegalovirus retinitis who had shown progression of retinitis despite extended intravenous induction single-drug therapy or alternating therapy with induction doses of ganciclovir or foscarnet at 6 weeks were subsequently treated with a combination of ganciclovir and foscarnet. The dosing regimes for induction combination therapy was ganciclover at 5 mg/kg every 12 hours and foscarnet at 60 mg/kg every 8 hours. Maintenance combination therapy was ganciclovir at 5 mg/kg every 12 to 24 hours and foscarnet at 90 to 120 mg/kg every day. Patients were observed closely for signs of a toxic effect or intolerance to the drug regimen. Results: All patients exhibited a favorable response to combination therapy, with complete healing of retinitis in 12 of 14 eyes and partial healing of retinitis with decreased border activity and a cessation of border advancement in two of 14 eye. Two of the nine patients stopped receiving combination therapy before completion of the study owing to their dissatisfaction with the time commitment. The regimen was otherwise well tolerated, with no significant medical toxic effects attributable to the drugs requiring cessation of therapy. Conclusions: Combination anticytomegalovrius therapy should be considered in those patients who have shown a poor clinical response to sustained single-drug induction therapy and alternating drug therapy. As survival time for patients with cytomegalovirus retinitis continues to improve, clinical resistance may become more common. Further work to delineate the optimal dosing and indications for combination therapy will be important.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 008343943

Download citation: RISBibTeXText

PMID: 8216016

DOI: 10.1001/archopht.1993.01090100067029


Related references

Therapy with a combination of intravitreal foscarnet and intravenous ganciclovir in clinically resistant cytomegalovirus retinitis and patients with acquired immunodeficiency syndrome. German Journal of Ophthalmology 5(6): 490-491, 1996

Treatment of Clinically Resistant Cytomegalovirus Retinitis in Aids Patients: Combination of Intravenous Ganciclovir and Intravitreal Foscarnet. European Journal of Ophthalmology 5(4): 199-203, 1995

Treatment of clinically resistant cytomegalovirus retinitis in AIDS patients: combination of intravenous ganciclovir and intravitreal foscarnet. European Journal of Ophthalmology 5(4): 199-203, 1995

Combined treatment with ganciclovir and foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome. Rinsho Ganka 52(5): 803-806, 1998

Ocular complications of the acquired immunodeficiency syndrome. Focus on the treatment of cytomegalovirus retinitis with ganciclovir and foscarnet. Pharmacy World and Science 15(2): 56-67, 1993

The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: The Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial. American Journal of Ophthalmology 131(4): 457-467, 2001

Intravitreal antiviral drug concentration after intravenous ganciclovir and foscarnet in acquired immunodeficiency syndrome patients with cytomegalovirus retinitis. Investigative Ophthalmology and Visual Science 35(4): 1892, 1994

Concurrent ganciclovir and foscarnet treatment for cytomegalovirus encephalitis and retinitis in an infant with acquired immunodeficiency syndrome: case report and review. Pediatric Infectious Disease Journal 16(8): 807-811, 1997

Treatment of cytomegalovirus retinitis clinically resistant to ganciclovir and foscarnet with intravitreal etoposide. Journal of Toxicology Cutaneous and Ocular Toxicology 19(1): 27-30, 2000

Treatment of clinically resistant cytomegalovirus retinitis with combined intravitreal injections of ganciclovir and foscarnet. American Journal of Ophthalmology 122(1): 121-123, 1996

Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir. American Journal of Ophthalmology 119(5): 587-596, 1995

Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS The cytomegalovirus retinitis retreatment trial. INFECTIOUS DISEASES SOCIETY OF AMERICA , NATIONAL INSTITUTES OF HEALTH , CENTERS FOR DISEASE CONTROL AND PREVENTION 3rd Conference on retroviruses and opportunistic infections : 164, 1996

Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Antimicrobial Agents and ChemoTherapy 33(5): 736-741, 1989

Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus. Journal of Pediatrics 120(3): 483-486, 1992

Foscarnet treatment of cytomegalovirus gastrointestinal infections in acquired immunodeficiency syndrome patients who have failed ganciclovir induction. American Journal of Gastroenterology 88(4): 542-548, 1993